BridgeBio Pharma Inc. (BBIO)
NASDAQ: BBIO · Pharmaceutical Preparations · Palo Alto, CA
Our rating: Positive
Call changed from Neutral to Positive at $74.95, moderate conviction, October 30, 2026.
Breaks if: The Positive call requires the Attruby commercial ramp to continue. It breaks if reported year-over-year revenue growth decelerates below 50% in either of the next two quarterly filings — broadly through mid-2027 — which would indicate plateau or competitive erosion well before the market's implied peak-sales estimate. A secondary trigger: if annualized free cash flow burn widens beyond $600M in any rolling four-quarter period through year-end 2027, the cash-runway equation deteriorates enough to compress the multiple independent of revenue progress.
Key figures
| Market value | $14.8B |
|---|---|
| Revenue, last 12 months | $946M |
| Net income, last 12 months | −$574M |
| Free cash flow, last 12 months | −$370M |
| Price to earnings | n/a |
| Free cash flow yield | −2.5% |
| Dividend yield | 0.0% |
| Operating margin | −38.5% |
| Return on equity | n/a |
| Beta to the S&P 500 | 1.00 |
| Volatility, annualized | 50.3% |
Reported quarters
| Quarter ending | Revenue | Year on year | Earnings per share | Free cash flow |
|---|---|---|---|---|
| September 30, 2026 | $353M | 192.6% | $-0.42 | −$44M |
| June 30, 2026 | $244M | 120.4% | $-0.78 | −$72M |
| March 31, 2026 | $195M | 66.8% | $-0.84 | −$197M |
| December 31, 2025 | $154M | 2521.2% | $-0.99 | −$56M |
| September 30, 2025 | $121M | 4318.0% | $-0.95 | −$110M |
| June 30, 2025 | $111M | 4999.9% | $-0.95 | −$81M |
| March 31, 2025 | $117M | −44.8% | $-0.88 | −$199M |
| December 31, 2024 | $6M | 237.1% | $-1.42 | −$195M |
Three-model forecasts for the next quarter
Written November 21, 2026, before the report. Each settles from the SEC filing.
- Revenue for the quarter is at least $1.27B: Claude 2%, Gemini 5%, Mistral 5%
- Diluted earnings per share are above zero: Claude 12%, Gemini 3%, Mistral 25%
- Free cash flow for the quarter is above zero: Claude 38%, Gemini 10%, Mistral 20%
16 ledger entries and 47 corporate events on record. Share price as of November 20, 2026. Research and education only. Not investment advice. Stoquity does not manage money or know your circumstances. Ratings, forecasts and lists are produced by software and AI models and can be wrong. Performance figures are hypothetical, measured on paper against a benchmark, and say nothing certain about the future.